3 Stocks in Focus: Zosano Pharma Corporation (ZSAN), Zynga Inc. (ZNGA), Novavax, Inc. (NVAX)

Zosano Pharma Corporation (ZSAN) climbed 41.09% during last trading as the stock added $0.83 to finish the day at $2.85 with about 35.15M shares changing hands, compared to its three month average trading volume of 1.2M. The $49.16M market cap company, which fluctuated between $2.02 and $3.49 during the day, currently situated 530.53% above its 52 week low of $0.45 and 0.71% away from its one year high of $3.49. The RSI of 90.61 indicates the stock is overbought at the current levels, sell for now.

Zosano Pharma Corporation, a clinical stage specialty pharmaceutical company, develops a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of various indications. The company’s product candidate is ZP-Triptan, a proprietary formulation of zolmitriptan used for the treatment of migraine, which has completed a Phase I clinical trial. Its product candidates also include ZP-PTH, a proprietary formulation of teriparatide that is used for the treatment of severe osteoporosis; and ZP-Glucagon, a proprietary formulation of glucagon that is intended for the emergency rescue of patients suffering from life-threatening, severe hypoglycemia. The company was founded in 2006 and is headquartered in Fremont, California.

Zynga Inc. (ZNGA) dropped $-0.03 to close the day at a new closing price of $2.67, a -1.11% decrease in value from its previous closing price that moved the stock 46.7% above its 52 week low of $1.84. A total of 31.62M shares exchanged hands during the day compared with its three month average trading volume of 10.01M. The stock, which fluctuated between $2.55 and $2.69 during the day, currently situated -13.31% below its 52 week high. The stock is up by 1.52% in the past one month and down by -6.32% over the past three months. With a one year target estimate of $3.27 and RSI of 54.79, the stock still has upside potential, making it a hold for now.

Zynga Inc. develops, markets, and operates social games as live services played on the Internet, social networking sites, and mobile platforms in the United States, North America, Asia, and the European Union. It offers its online social games primarily under the Slots, Words With Friends, Zynga Poker, and FarmVille franchises. The company’s games are accessible on mobile platforms, Facebook, and other social networks, as well as Zynga.com. It also provides advertising services to advertising agencies and brokers. The company was formerly known as Zynga Game Network Inc. and changed its name to Zynga Inc. in November 2010. Zynga Inc. was founded in 2007 and is headquartered in San Francisco, California.

Novavax, Inc. (NVAX) had a light trading with around 31.31M shares changing hands compared to its three month average trading volume of 6.39M. The stock traded between $1.41 and $1.73 before closing at the price of $1.62 with 14.08% change on the day. The Gaithersburg Maryland 20878 based company is currently trading 39.66% above its 52 week low of $1.16 and -80.92% below its 52 week high of $8.49. Both the RSI indicator and target price of 74.34 and $3.29 respectively, lead us to believe that it could drop over the coming weeks.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

 

Stocks Alert: Novavax, Inc. (NVAX), Peregrine Pharmaceuticals, Inc. (PPHM), Spirit Realty Capital, Inc. (SRC)

Novavax, Inc. (NVAX) grew with the stock adding 2.24% or $0.03 to close at $1.37 on light trading volume of 5.32M compared its three months average trading volume of 6.53M. The Gaithersburg Maryland 20878 based company operating under the Biotechnology industry has been trending down for the last 52 weeks, with the shares price now -70.28% down for the period and up by 8.73% so far this year. With price target of $3.29 and a 18.1% rebound from 52-week low, Novavax, Inc. has plenty of upside potential, making it a hold with a view buy.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Peregrine Pharmaceuticals, Inc. (PPHM) gained $0.01 to close the day at a new closing price of $0.37, a 3.84% increase in value from its previous closing price that moved the stock 32.21% above its 52 week low of $0.282. A total of 5.31M shares exchanged hands during the day compared with its three month average trading volume of 2.01M. The stock, which fluctuated between $0.3553 and $0.3825 during the day, currently situated -66.95% below its 52 week high. The stock is up by 27.66% in the past one month and up by 15.69% over the past three months. With a one year target estimate of $1.25 and RSI of 73.74, the stock still has upside potential, making it a sell for now.

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment of cancer in the United States. It’s lead immunotherapy candidate bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company also provides integrated current good manufacturing practices services from cell line development to commercial bio manufacturing for its third-party customers. In addition, its services comprise cGMP clinical and commercial manufacturing utilizing stainless steel and single use bioreactor technology, purification, bulk packaging, stability testing, regulatory strategy and related support. The company has license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; Merck KGaA; and National Comprehensive Cancer Network, as well as collaboration agreement with AstraZeneca PLC and Memorial Sloan Kettering Cancer Center. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

Spirit Realty Capital, Inc. (SRC) shares were down in last trading by -0.09% to $10.84. It experienced higher than average volume on day. The stock increased in value by almost 2.26% over the past week and fell -1.63% in the past month. It is currently trading 1.54% above its 50 day moving average and -7.24% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -20.03% decrease in value from its one year high of $13.97. The RSI indicator value of 55.08, lead us to believe that it is a hold for now.

Spirit Realty Capital, Inc. is a publicly traded real estate investment trust. The firm primarily acquires across the United States single tenant operationally essential real estate, which refers to generally free-standing, commercial real estate facilities where tenants conduct retail, service or distribution activities that are essential to the generation of their sales and profits. The firm was formerly known as Spirit Finance Corp. Spirit Realty Capital, Inc. was formed on August 14, 2003 and is domiciled in the United States.

 

3 Notable Runners: QEP Resources, Inc. (QEP), Uranium Energy Corp. (UEC), Novavax, Inc. (NVAX)

QEP Resources, Inc. (QEP) continued its upward trend with the stock climbing 0.95% or $0.16 to close the day at $16.93 on lower than average trading volume of 2.96M shares, compared to its three month average trading volume of 3.07M. The Denver Colorado 80265 based company has been outperforming the oil & gas pipelines companies by 5.548% for last three months and its recent gains have offset losses to -8.04% YTD, versus the oil & gas pipelines industry which is up 4.76% for the same period. The RSI of 36.67 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

QEP Resources, Inc., through its subsidiaries, operates as a natural gas and crude oil exploration and production company in the United States. The company conducts exploration and production activities in the Pinedale Anticline in western Wyoming; the Williston Basin in North Dakota; the Uinta Basin in eastern Utah; the Permian Basin in western Texas; the Haynesville/Cotton Valley in northwestern Louisiana; and other proven properties in Wyoming, Utah, and Colorado. As of December 31, 2015, it had estimated proved reserves of 3,620.2 billion cubic feet of natural gas equivalents. The company sells its gas, oil, and natural gas liquids (NGL) to various customers, including gas-marketing firms, industrial users, local-distribution companies, crude oil refiners, and remarketers, as well as markets affiliate and third-party gas, oil, and NGL volumes. In addition, it operates a gas gathering system and an underground gas storage facility. QEP Resources, Inc. is headquartered in Denver, Colorado.

Uranium Energy Corp. (UEC) had a active trading with around 2.96M shares changing hands compared to its three month average trading volume of 2.06M. The stock traded between $1.67 and $1.76 before closing at the price of $1.7 with 2.41% change on the day. The Vancouver British Columbia V6E 2Y3 based company is currently trading 146.38% above its 52 week low of $0.69 and -6.59% below its 52 week high of $1.82. Both the RSI indicator and target price of 60.4 and $2.79 respectively, lead us to believe that it should be put on hold over the coming weeks.

Uranium Energy Corp. engages in the exploration, pre-extraction, extraction, and processing of uranium concentrates on projects located in the United States and the Republic of Paraguay. As of July 31, 2016, it had mineral rights in uranium projects located in the states of Arizona, Colorado, New Mexico, Texas, and Wyoming, as well as in the Republic of Paraguay. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. Uranium Energy Corp. was incorporated in 2003 and is based in Corpus Christi, Texas.

Novavax, Inc. (NVAX) traded within a range of $1.29 to $1.33 after opening the day at $1.29. The company has seen its stock increase in value by 4.76% so far this year. The stock was up close to 0.76% on light volume in last trading session and closed at $1.32 per share. After the recent gain, the stock is currently holding -84.45% below its 52 week high of $8.49 and 13.79% above its 12-month low of $1.16. The shares are down by over -8.97% in the last three months, and the RSI indicator value of 45.93 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

 

Equities Trend Analysis: Ocean Rig UDW LLC (ORIG), Novavax, Inc. (NVAX), Cerulean Pharma Inc. (CERU)

Ocean Rig UDW LLC (ORIG) grew with the stock adding 1.9% or $0.02 to close at $1.07 on active trading volume of 3.51M compared its three months average trading volume of 3.39M. The Nicosia NI 1075 based company operating under the Oil & Gas Drilling & Exploration industry has been trending up for the last 52 weeks, with the shares price now 30.49% up for the period and down by -38.51% so far this year. With price target of $0 and a 62.12% rebound from 52-week low, Ocean Rig UDW LLC has plenty of upside potential, making it a hold with a view buy.

Ocean Rig UDW LLC was founded in 2010 and is based in Houston, Texas. Ocean Rig UDW LLC operates as a subsidiary of Ocean Rig UDW Inc.

Novavax, Inc. (NVAX) had a light trading with around 3.48M shares changing hands compared to its three month average trading volume of 7.04M. The stock traded between $1.28 and $1.33 before closing at the price of $1.31 with 0% change on the day. The Gaithersburg Maryland 20878 based company is currently trading 12.93% above its 52 week low of $1.16 and -84.57% below its 52 week high of $8.49. Both the RSI indicator and target price of  and $3.29 respectively, lead us to believe that it could rise over the coming weeks.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Cerulean Pharma Inc. (CERU) saw its value increase by 14.66% as the stock gained $0.17 to finish the day at a closing price of $1.33. The stock was higher in trading and has fluctuated between $0.63-$4.33 per share for the past year. The shares, which traded within a range of $1.05 to $1.35 during the day, are up by 90.52% in the past three months and down by -53.5% over the past six months. It is currently trading 52.28% above its 20 day moving average and 64.97% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $5.5 a share over the next twelve months. The current relative strength index (RSI) reading is 76.45.The technical indicator do not lead us to believe the stock will see more gains any time soon.

Cerulean Pharma Inc., a clinical-stage company, develops nanotechnology-based therapeutics in the areas of oncology and other diseases in the United States. The company’s lead product candidate is CRLX101, a tumor targeted nanoparticle-drug conjugate (NDC), which is in Phase 2 clinical development in patients with renal cell carcinoma; and in Phase 2 and Phase 1b clinical development in patients with ovarian cancer. It is also developing CRLX301, a platform-generated NDC clinical candidate, which is in Phase 1/2a clinical trials. The company has a strategic collaboration with Novartis to develop nanoparticle-drug conjugates for various cancer tumor targets. The company was formerly known as Tempo Pharmaceuticals, Inc. and changed its name to Cerulean Pharma Inc. in October 2008. Cerulean Pharma Inc. was incorporated in 2005 and is based in Waltham, Massachusetts.

 

Trader’s Round Up: EnteroMedics Inc. (ETRM), Novavax, Inc. (NVAX), Ascena Retail Group, Inc. (ASNA)

EnteroMedics Inc. (ETRM) grew with the stock adding 1.33% or $0.1 to close at $7.64 on active trading volume of 2.73M compared its three months average trading volume of 12.5M. The St. Paul Minnesota 55113 based company operating under the Medical Appliances & Equipment industry has been trending up for the last 52 weeks, with the shares price now 594.55% up for the period and up by 282% so far this year. With price target of $140 and a 19000% rebound from 52-week low, EnteroMedics Inc. has plenty of upside potential, making it a hold with a view buy.

EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. The company develops the Maestro Rechargeable System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. It has collaboration with Mayo Clinic for the development and testing of products for the treatment of obesity. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

Novavax, Inc. (NVAX) dropped $0 to close the day at a new closing price of $1.33, a 0% decrease in value from its previous closing price that moved the stock 14.66% above its 52 week low of $1.16. A total of 2.71M shares exchanged hands during the day compared with its three month average trading volume of 7.36M. The stock, which fluctuated between $1.3 and $1.35 during the day, currently situated -84.33% below its 52 week high. The stock is up by 0.76% in the past one month and up by 9.02% over the past three months. With a one year target estimate of $3.29 and RSI of 47.36, the stock still has upside potential, making it a hold for now.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Ascena Retail Group, Inc. (ASNA) shares were down in last trading by -0.2% to $4.91. It experienced lighter than average volume on day. The stock increased in value by almost 6.51% over the past week and fell -18.71% in the past month. It is currently trading -20.07% below its 50 day moving average and -28.32% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -56.39% decrease in value from its one year high of $11.26. The RSI indicator value of 36.3, lead us to believe that it is a hold for now.

Ascena Retail Group, Inc., through its subsidiaries, operates as a specialty retailer of apparel, shoes, and accessories for women and tween girls in the United States, Canada, and Puerto Rico. The company operates through six segments: ANN, Justice, Lane Bryant, maurices, dressbarn, and Catherines. It creates, designs, and develops a range of merchandise, including apparel, accessories, footwear, and intimates; lifestyle products comprising cosmetics, bedroom furnishings, and electronics; and wear-to-work, casual sportswear, footwear, and social occasion apparel. The company also offers casual clothing, career wear, dressy apparel, and active wear, as well as special occasion and classic apparel. Its principal brands comprise ANN TAYLOR, LOFT, ANN TAYLOR LOFT, LOU & GREY, JUSTICE, LANE BRYANT, LANE BRYANT OUTLET, CACIQUE, RIGHT FIT, MAURICES, DRESSBARN, CATHERINES, CATHERINES PLUS SIZES, MAGGIE BARNES, LIZ&ME, SERENADA, DRESSBAR, 6th & LANE, and MAURICES IN MOTION. As of July 30, 2016, the company operated approximately 4,900 stores. It also offers its products through its Websites, including anntaylor.com, LOFT.com, louandgrey.com, shopjustice.com, lanebryant.com, cacique.com, maurices.com, dressbarn.com, and catherines.com. The company was formerly known as Dress Barn, Inc. and changed its name to Ascena Retail Group, Inc. in January 2011. Ascena Retail Group, Inc. was founded in 1962 and is based in Mahwah, New Jersey.

 

Stocks in Review: Novavax, Inc. (NVAX), Sanchez Energy Corporation (SN), SLM Corporation (SLM)

Novavax, Inc. (NVAX) traded within a range of $1.28 to $1.33 after opening the day at $1.3. The company has seen its stock increase in value by 5.56% so far this year. The stock was up close to 3.91% on light volume in last trading session and closed at $1.33 per share. After the recent gain, the stock is currently holding -84.33% below its 52 week high of $8.49 and 14.66% above its 12-month low of $1.16. The shares are down by over -0.75% in the last three months, and the RSI indicator value of 49.82 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Sanchez Energy Corporation (SN) continued its upward trend with the stock climbing 2.12% or $0.28 to close the day at $13.46 on light trading volume of 3.17M shares, compared to its three month average trading volume of 3.45M. The Houston Texas 77002 based company has been outperforming the independent oil & gas group over the past 52 weeks, with the stock gaining 306.65%, compared to the industry which has advanced 42.02% over the same period. With RSI of 64.32, the stock should still continue to rise and get closer to its one year target estimate of $15.64, making it a hold for now.

Sanchez Energy Corporation, an independent exploration and production company, engages in the exploration, acquisition, and development of oil and natural gas resources in the onshore U.S. Gulf Coast. It holds a 93% working interest in the Eagle Ford Shale, which consists of approximately 200,000 net leasehold acres in the oil and condensate, or black oil and volatile oil located in South Texas; and a 65% working interest in the Tuscaloosa Marine Shale covering an area of approximately 62,000 net leasehold acres situated in Mississippi and Louisiana. The company was founded in 2011 and is headquartered in Houston, Texas.

SLM Corporation (SLM) gained $0.18 to close the day at a new closing price of $12.04, a 1.52% increase in value from its previous closing price that moved the stock 125.47% above its 52 week low of $5.34. A total of 3.16M shares exchanged hands during the day compared with its three month average trading volume of 4.36M. The stock, which fluctuated between $11.9 and $12.07 during the day, currently situated -0.99% below its 52 week high. The stock is up by 4.7% in the past one month and up by 71.27% over the past three months. With a one year target estimate of $12.95 and RSI of 67.06, the stock still has upside potential, making it a hold for now.

SLM Corporation, together with its subsidiaries, operates as a saving, planning, and paying for education company in the United States. It offers private education loans to students and their families. The company also provides banking products, such as certificates of deposits, money market deposit accounts, and high yield savings accounts; and a consumer savings network that offers financial rewards on everyday purchases to help families save for college. SLM Corporation was founded in 1972 and is headquartered in Newark, Delaware.

 

Stocks in Review: The Goodyear Tire & Rubber Company (GT), Kohl’s Corporation (KSS), Novavax, Inc. (NVAX)

The Goodyear Tire & Rubber Company (GT) traded within a range of $31.9 to $32.7 after opening the day at $32.5. The company has seen its stock increase in value by 4.35% so far this year. The stock was down close to -0.86% on active volume in last trading session and closed at $32.11 per share. After the recent fall, the stock is currently holding -3.44% below its 52 week high of $33.36 and 33.26% above its 12-month low of $24.31. The shares are up by over 10.96% in the last three months, and the RSI indicator value of 59.53 is neither bullish nor bearish, tempting investors to stay on the sidelines.

The Goodyear Tire & Rubber Company, together with its subsidiaries, develops, manufactures, markets, and distributes tires, and related products and services. The company offers various lines of rubber tires for automobiles, trucks, buses, aircrafts, motorcycles, earthmoving and mining equipment, farm implements, industrial equipment, and various other applications under the Goodyear, Dunlop, Kelly, Debica, Sava, Fulda, and various other Goodyear owned house brands, as well as private-label brands. It also retreads truck, aviation, and off-the-road tires; manufactures and sells tread rubber and other tire retreading materials; manufactures and sells rubber-related chemicals; and provides automotive repair services, and miscellaneous other products and services. In addition, the company sells natural rubber products. It operates approximately 1,100 tire and auto service center outlets, which offer products for retail sale, and provides automotive repair and other services. The company sells its products worldwide through a network of dealers, regional distributors, retail outlets, and retailers. The Goodyear Tire & Rubber Company was founded in 1898 and is headquartered in Akron, Ohio.

Kohl’s Corporation (KSS) failed to extend gains with the stock declining -0.88% or $-0.35 to close the day at $39.48 on light trading volume of 3.34M shares, compared to its three month average trading volume of 4.81M. The Menomonee Falls Wisconsin 53051 based company has been underperforming the department stores group over the past 52 weeks, with the stock losing -18.08%, compared to the industry which has dropped -6.71% over the same period. With RSI of 30.66, the stock should still continue to rise and get closer to its one year target estimate of $46.29, making it a hold for now.

Kohl’s Corporation operates department stores in the United States. It offers private label, exclusive, and national brand apparel, footwear, accessories, beauty, and home products to children, men, and women customers. The company also sells its products online through Website Kohls.com. As of January 30, 2016, it operated 1,164 department stores in 49 states. Kohl’s Corporation was founded in 1962 and is headquartered in Menomonee Falls, Wisconsin.

Novavax, Inc. (NVAX) dropped $-0.01 to close the day at a new closing price of $1.3, a -0.76% decrease in value from its previous closing price that moved the stock 12.07% above its 52 week low of $1.16. A total of 3.33M shares exchanged hands during the day compared with its three month average trading volume of 7.64M. The stock, which fluctuated between $1.29 and $1.32 during the day, currently situated -84.69% below its 52 week high. The stock is up by 3.17% in the past one month and down by -14.47% over the past three months. With a one year target estimate of $3.29 and RSI of 47.49, the stock still has upside potential, making it a hold for now.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

 

Eye Catching Stocks: Novavax, Inc. (NVAX), People’s United Financial, Inc. (PBCT), Twilio Inc. (TWLO)

Novavax, Inc. (NVAX) managed to rebound with the stock climbing 0.74% or $0.01 to close the day at $1.36 on light trading volume of 5.45M shares, compared to its three month average trading volume of 7.82M. The Gaithersburg Maryland 20878 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -75.93%, compared to the industry which has advanced 2.66% over the same period. With RSI of 50.44, the stock should still continue to rise and get closer to its one year target estimate of $3.29, making it a hold for now.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

People’s United Financial, Inc. (PBCT) climbed 1.06% during last trading as the stock added $0.2 to finish the day at $19.09 with about 5.4M shares changing hands, compared to its three month average trading volume of 3.96M. The $6.08B market cap company, which fluctuated between $18.91 and $19.16 during the day, currently situated 46.49% above its 52 week low of $13.7 and -5.17% away from its one year high of $20.13. The RSI of 49.27 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

People’s United Financial, Inc. operates as the bank holding company for People’s United Bank, National Association that provides commercial banking, retail banking, and wealth management services to individual, corporate, and municipal customers. The company operates in two segments, Commercial Banking and Retail Banking. The Commercial Banking segment offers commercial real estate lending, commercial and industrial lending, and commercial deposit gathering services. This segment also provides equipment financing; cash management, correspondent banking, and municipal banking services; and institutional trust, corporate trust, private banking, and insurance services. The Retail Banking segment offers consumer lending, including residential mortgage and home equity lending; and consumer deposit gathering services. This segment also provides brokerage, financial advisory, investment management, life insurance, and non-institutional trust services. In addition, the company offers online banking, investment trading, and telephone banking services. It operates through a network of 396 branches and 594 ATMs in Connecticut, southeastern New York, Massachusetts, Vermont, New Hampshire, and Maine. People’s United Financial, Inc. was founded in 1842 and is headquartered in Bridgeport, Connecticut.

Twilio Inc. (TWLO) saw its value increase by 1.11% as the stock gained $0.32 to finish the day at a closing price of $29.05. The stock was higher in trading and has fluctuated between $23.66-$70.96 per share for the past year. The shares, which traded within a range of $28.83 to $30.47 during the day, are down by -28.68% in the past three months and down by -28.08% over the past six months. It is currently trading 1.54% above its 20 day moving average and -6% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $38.44 a share over the next twelve months. The current relative strength index (RSI) reading is 46.8. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Twilio Inc. provides cloud communications platform that enables developers to build, scale, and operate communications within software applications through the cloud as a pay-as-you-go service in the United States and internationally. It offers programmable communications cloud software that enables developers to embed voice, messaging, video, and authentication capabilities into their applications through application programming interfaces. The company also provides use case products, such as a two-factor authentication solution. Twilio Inc. was founded in 2008 and is headquartered San Francisco, California.

 

Momentum Stocks: Schlumberger Limited (SLB), Pacific Biosciences of California, Inc. (PACB), Novavax, Inc. (NVAX)

Schlumberger Limited (SLB) grew with the stock adding 0.37% or $0.31 to close at $84.58 on active trading volume of 6.02M compared its three months average trading volume of 5.41M. The Houston Texas 77056 based company operating under the Oil & Gas Equipment & Services industry has been trending up for the last 52 weeks, with the shares price now 37.13% up for the period and up by 0.75% so far this year. With price target of $96.12 and a 37.29% rebound from 52-week low, Schlumberger Limited has plenty of upside potential, making it a hold with a view buy.

Schlumberger Limited supplies technology, integrated project management, and information solutions to the oil and gas exploration and production industry worldwide. Its Reservoir Characterization Group segment provides reservoir imaging, monitoring, and development services; wireline technologies for open and cased-hole services; exploration and production pressure and flow-rate measurement services comprising surface and downhole services; software integrated solutions, such as software, consulting, information management, and IT infrastructure services; consulting services for reservoir characterization, field development planning, and production enhancement; and petrotechnical data services and training solutions, as well as integrated management services. Its Drilling Group segment designs, manufactures, and markets roller cone and fixed cutter drill bits; supplies drilling fluid systems; provides pressure drilling and underbalanced drilling solutions, and environmental services and products; mud logging services; land drilling rigs and related support services; and well planning and drilling, engineering, supervision, logistics, procurement, contracting, and drilling rig management services, as well as bottom-hole-assembly, borehole-enlargement technologies, impact tools, tubulars, and tubular services. Its Production Group segment provides well services comprising pressure pumping, well cementing, stimulation, and intervention services; well completion services and equipment that include packers, safety valves, and sand control technology, as well as completions technology and equipment; artificial lifts; coiled tubing equipment and services, and slickline services; development, management, and environmental protection services for water resources; and integrated production and production management services. The company was formerly known as Socie´te´ de Prospection E´lectrique. Schlumberger Limited was founded in 1926 and is based in Houston, Texas.

Pacific Biosciences of California, Inc. (PACB) had a active trading with around 5.94M shares changing hands compared to its three month average trading volume of 1.73M. The stock traded between $4.4 and $4.99 before closing at the price of $4.53 with -4.63% change on the day. The Menlo Park California 94025 based company is currently trading 20.48% above its 52 week low of $3.76 and -67.6% below its 52 week high of $13.98. Both the RSI indicator and target price of  and $7.46 respectively, lead us to believe that it could rise over the coming weeks.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company’s single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes biochemical sequencing reactions. The company also provides consumable products, including sealed and packaged SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits to run the PacBio RS II or Sequel System. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distributors in Asia. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Novavax, Inc. (NVAX) saw its value decrease by 0% as the stock dropped $0 to finish the day at a closing price of $1.35. The stock was lighter in trading and has fluctuated between $1.16-$8.49 per share for the past year. The shares, which traded within a range of $1.31 to $1.37 during the day, are down by -11.18% in the past three months and down by -81.51% over the past six months. It is currently trading -0.33% below its 20 day moving average and 0.04% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $3.29 a share over the next twelve months. The current relative strength index (RSI) reading is 49.79.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

 

Stocks To Track: Host Hotels & Resorts, Inc. (HST), Novavax, Inc. (NVAX), Alcoa Corporation (AA)

Host Hotels & Resorts, Inc. (HST) fell -0.49% during last trading as the stock lost $-0.09 to finish the day at $18.24 with about 5.35M shares changing hands, compared to its three month average trading volume of 10.75M. The $13.41B market cap company, which fluctuated between $18.12 and $18.31 during the day, currently situated 50.22% above its 52 week low of $12.98 and -6.37% away from its one year high of $19.51. The RSI of 51.32 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Host Hotels & Resorts, Inc. is a publicly owned real estate investment trust (REIT). The firm primarily engages in the ownership and operation of hotel properties. It invests in the real estate markets of United States. It also invests in Canada, Mexico, Chile, the United Kingdom, Italy, Spain, and Poland. The firm primarily invests in luxury and upper upscale hotels. It was formerly known as Host Marriott Corporation. Host Hotels & Resorts, Inc. was founded in 1927 and is based in Bethesda, Maryland.

Novavax, Inc. (NVAX) dropped $0 to close the day at a new closing price of $1.35, a 0% decrease in value from its previous closing price that moved the stock 16.38% above its 52 week low of $1.16. A total of 5.3M shares exchanged hands during the day compared with its three month average trading volume of 7.92M. The stock, which fluctuated between $1.33 and $1.39 during the day, currently situated -84.1% below its 52 week high. The stock is down by -4.93% in the past one month and down by -14.01% over the past three months. With a one year target estimate of $3.29 and RSI of 49.24, the stock still has upside potential, making it a hold for now.

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Alcoa Corporation (AA) had a active trading with around 5.24M shares changing hands compared to its three month average trading volume of 4.52M. The stock traded between $35.46 and $36.4 before closing at the price of $36.29 with 1.77% change on the day. The New York New York 10022 based company is currently trading 82.16% above its 52 week low of $20 and 1.54% above its 52 week high of $36.4. Both the RSI indicator and target price of 73.98 and $32.63 respectively, lead us to believe that it could drop over the coming weeks.

Alcoa Corporation engages in mining and production of bauxite, alumina, and aluminum products. It owns seven bauxite mines located near principal Atlantic and Pacific markets; and provides smelter grade alumina to aluminum manufacturers in Asia, the Middle East, and Latin America, as well as non-metallurgical grade alumina for industrial chemical operations in North America, Latin America, Europe, and Asia. The company is also involved in mining, refining, smelting, casting, and rolling aluminum products; production of aluminum billets, foundry ingots, rolling slabs, rods, powders, and proprietary alloys; and generation and sale of renewable energy. In addition, it produces and sells rolled aluminum sheets used in packaging, including aluminum bottles and food cans. The company was formerly known as Alcoa Upstream Corporation and changed its name to Alcoa Corporation in October 2016. Alcoa Corporation is based in New York, New York.